ChiCTR2000035157 版本V1.0 版本创建时间2020/08/02 14:19:36 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000035157 

最近更新日期:

Date of Last Refreshed on:

2020-08-02 14:19:33 

注册时间:

Date of Registration:

1990-01-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

审核中(五)0.2%罗哌卡因用于超声引导下正中神经阻滞的半数有效容量

Public title:

Median effective volume of 0. 2% ropivacaine employed in the ultrasound-guided median nerve block

注册题目简写:

English Acronym:

研究课题的正式科学名称:

罗哌卡因用于超声引导下正中神经阻滞的有效容量研究

Scientific title:

Study on the effective volume of ropivacaine for ultrasound guided median nerve block

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈杭 

研究负责人:

涂生芬 

Applicant:

Chen Hang 

Study leader:

Tu Shengfen 

申请注册联系人电话:

Applicant telephone:

+86 18523443212

研究负责人电话:

Study leader's telephone:

+86 13983416114

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

595494227@qq.com

研究负责人电子邮件:

Study leader's E-mail:

519194496@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆渝中区中山二路136号

研究负责人通讯地址:

重庆渝中区中山二路136号

Applicant address:

136 Second Zhongshan Road, Yuzhong, Chongqing, China

Study leader's address:

136 Second Zhongshan Road, Yuzhong, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属儿童医院

Applicant's institution:

Children′s Hospital Affiliated Chongqing Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020-78

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属儿童医院伦理委员会

Name of the ethic committee:

Institutional Review Board of Children′s Hospital Affiliated Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-07-17 00:00:00

伦理委员会联系人:

卢仲毅

Contact Name of the ethic committee:

Lu Zhongyi

伦理委员会联系地址:

重庆渝中区中山二路136号

Contact Address of the ethic committee:

136 Second Zhongshan Road, Yuzhong, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属儿童医院

Primary sponsor:

Children′s Hospital Affiliated Chongqing Medical University

研究实施负责(组长)单位地址:

重庆渝中区中山二路136号

Primary sponsor's address:

136 Second Zhongshan Road, Yuzhong, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属儿童医院

具体地址:

渝中区中山二路136号

Institution
hospital:

Children's Hospital of Chongqing Medical University

Address:

136 Second Zhongshan Road, Yuzhong District

经费或物资来源:

自筹

Source(s) of funding:

raise independently

Target disease:

Trigger finger

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

不同剂量对照 

Study design:

Dose comparison 

研究目的:

测定超声引导下正中神经阻滞用于小儿拇指扳机指手术时,测定0.2%罗哌卡因的半数有效容量( EV50 ),以为临床用药提供参考。  

Objectives of Study:

Determination of the 50% effective volume (EV50) of 0.2% ropivacaine for ultrasound-guided median nerve block in pediatric trigger finger surgery to provide a reference for clinical medication.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

a.在重庆医科大学附属儿童医院择期行拇指扳机指手术的患儿
b.纳入ASA分级I-II级,年龄1-3岁的患儿。

Inclusion criteria

A. Children who are scheduled to undergo trigger finger surgery in children's Hospital affiliated to Chongqing Medical University
B. Children aged 1-3 years were included in ASA grade I-II.

排除标准:

a.凝血功能异常,
b.存在上肢神经损伤,
c.穿刺部位有感染史,
d.已知罗哌卡因过敏,
e.存在上呼吸道感染史,
父母拒绝参加本次实验研究。

Exclusion criteria:

A. Abnormal coagulation function,
B. The presence of upper limb nerve injury,
C. The puncture site has a history of infection,
D. Known allergy to ropivacaine,
E. A history of upper respiratory tract infection,
Parents refused to participate in the study.

研究实施时间:

Study execute time:

From 2020-07-20 00:00:00 To 2020-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-07-20 00:00:00 To 2020-10-30 00:00:00  

干预措施:

Interventions:

组别:

病例

样本量:

50

Group:

Case series

Sample size:

干预措施:

序贯法

干预措施代码:

Intervention:

Sequential method

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

重庆医科大学附属儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Children's Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

罗哌卡因90%最低有效浓度,90%最低有效容量,以及0.2%罗哌卡因的半数有效容量

指标类型:

主要指标

Outcome:

MEC90, MEV90, EV50

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

成功率

指标类型:

次要指标

Outcome:

rate of success

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

次要指标

Outcome:

Complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

镇静复苏时间

指标类型:

次要指标

Outcome:

Sedation recovery time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 1 years
最大 Max age 3 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用序贯法-下一个病人的药量由上个病人的效果决定

Randomization Procedure (please state who generates the random number sequence and by what method):

Statistical analysis was performed by Dixon's sequential method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

及时公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

real time access

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病理记录表,专业的电子数据库,运用序贯法和SPSS进行统计分析

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form and professional electronic database, using sequential method and SPSS for statistical analysis

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-02 14:19:33